Target intelligence / Profile preview

Poly [ADP-ribose] polymerase 1, Poly [ADP-ribose] polymerase 2 (PARP1, PARP2)

Target
PARP1, PARP2
Molecular classification
Enzyme, DNA repair enzyme, PARP protein family, Chromatin regulator
01

Overview

Poly [ADP-ribose] polymerase 1 (PARP1) and Poly [ADP-ribose] polymerase 2 (PARP2) are enzymes primarily involved in the detection and repair of single-strand DNA breaks through the base excision repair pathway. Upon binding to damaged DNA, they catalyze the transfer of ADP-ribose units from NAD\(^+\) to target proteins (including themselves), producing poly(ADP-ribose) chains that serve as signals to recruit and assemble DNA repair complexes. PARP1 accounts for the majority of PARP activity in cells, while PARP2 contributes to a lesser extent but fulfills complementary and overlapping roles, including chromatin regulation and maintenance of genome stability. Inhibition of these proteins is a validated therapeutic strategy in cancers with defects in homologous recombination repair, such as those carrying BRCA1/2 mutations.

Other names
ADPRTPARPPoly (ADP-ribose) synthetase 1ADPRT2Poly (ADP-ribose) synthetase 2
02

Mechanism of action

Inhibition of PARP1/2 enzymatic activity leads to accumulation of DNA damage in cancer cells deficient in homologous recombination repair (synthetic lethality). Blocking poly(ADP-ribosyl)ation prevents recruitment of DNA repair proteins, resulting in cell death, particularly in BRCA-mutant or other HR-deficient cancers.

03

Biological functions

DNA repair (notably base excision repair and single-strand break repair)Regulation of genomic stabilityRegulation of chromatin structureApoptosis and programmed cell deathEpigenetic regulationCellular response to stress or DNA damage
04

Disease associations

CancerInflammationNeurodegenerative diseaseCardiovascular disease (linked to cell death pathways)Other diseases involving defects in DNA repair or genomic instability
05

Safety considerations

Myelosuppression (anemia, neutropenia, thrombocytopenia)Gastrointestinal toxicity (nausea, vomiting)FatiguePotential for development of resistance in cancer therapyRisk of secondary malignancies (rare)
06

Interacting drugs

Olaparib

5 more in the full profile.

07

Biomarkers

BRCA1/2 mutation status (predicts response to PARP inhibitors)Homologous recombination deficiency (HRD) score

Beyond the preview

Go deeper on Poly [ADP-ribose] polymerase 1, Poly [ADP-ribose] polymerase 2 (PARP1, PARP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poly [ADP-ribose] polymerase 1, Poly [ADP-ribose] polymerase 2 (PARP1, PARP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call